Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Paul Hudson
CEOPaul Hudson
Employees
84,587
Employees84,587
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
84,587
Employees84,587

SNY Key Statistics

Market cap
122.70B
Market cap122.70B
Price-Earnings ratio
12.22
Price-Earnings ratio12.22
Dividend yield
3.25%
Dividend yield3.25%
Average volume
2.37M
Average volume2.37M
High today
$50.61
High today$50.61
Low today
$49.25
Low today$49.25
Open price
$50.02
Open price$50.02
Volume
1.86M
Volume1.86M
52 Week high
$60.12
52 Week high$60.12
52 Week low
$44.62
52 Week low$44.62

Stock Snapshot

As of today, Sanofi(SNY) shares are valued at $50.06. The company's market cap stands at 122.7B, with a P/E ratio of 12.22 and a dividend yield of 3.3%.

As of 2025-11-25, Sanofi(SNY) stock has fluctuated between $49.25 and $50.61. The current price stands at $50.06, placing the stock +1.7% above today's low and -1.1% off the high.

The Sanofi(SNY)'s current trading volume is 1.86M, compared to an average daily volume of 2.37M.

In the last year, Sanofi(SNY) shares hit a 52-week high of $60.12 and a 52-week low of $44.62.

In the last year, Sanofi(SNY) shares hit a 52-week high of $60.12 and a 52-week low of $44.62.

SNY News

TipRanks 2h
Sanofi’s Parisian HQ raided in French tax fraud probe, Le Monde reports

Sanofi’s (SNY) Parisian headquarters were searched on Tuesday by about 30 judicial tax officers of the National Anti-Fraud Office, two magistrates of the Nation...

TipRanks 7h
Regeneron, Sanofi announce European Commission approval for Dupixent

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urtic...

Nasdaq 11h
Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents

(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a...

Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents

More SNY News

TipRanks 5d
Texas AG sues Sanofi, Bristol Myers over alleged Plavix inefficacy

Texas Attorney General Ken Paxton filed a lawsuit against pharmaceutical companies Sanofi (SNY) and Bristol-Myers Squibb (BMY) for failing to disclose that thei...

TipRanks 7d
Sanofi Advances with Dupixent and Teizeild Approvals in November 2025

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.